Resuming Nortriptyline After 3-Week Discontinuation
After a 3-week abrupt discontinuation of nortriptyline 100 mg, you should restart at a lower dose (25-50 mg daily) and gradually titrate upward rather than resuming at the full 100 mg dose, as the abrupt cessation without taper increases risk of symptom recurrence and the patient has been off medication long enough to lose tolerance to the full therapeutic dose.
Rationale for Dose Reduction on Restart
The FDA labeling for nortriptyline explicitly states that "the physician should initiate dosage at a low level and increase it gradually" 1. While this guidance primarily addresses initial treatment, the same principle applies after a 3-week medication-free period for several key reasons:
- Loss of physiologic adaptation: After 3 weeks off medication, the patient's neuroreceptor sensitivity has likely shifted back toward baseline, making them more susceptible to side effects at the previous therapeutic dose
- Cardiovascular safety: Nortriptyline at 100 mg is at the upper end of the typical dosing range, and tricyclic antidepressants carry cardiac risks that necessitate cautious dose escalation 1
- Plasma level considerations: The FDA label emphasizes that doses above 100 mg require plasma level monitoring (target 50-150 ng/mL), and restarting at 100 mg without current levels could risk toxicity 1
Recommended Restart Protocol
Start at 25-50 mg daily and increase by 25 mg every 3-7 days as tolerated, monitoring for:
- Anticholinergic effects (dry mouth, constipation, urinary retention)
- Cardiovascular effects (orthostatic hypotension, tachycardia, QT prolongation)
- CNS effects (sedation, confusion, especially in elderly)
- Return of depressive or anxiety symptoms
Target the previous therapeutic dose of 100 mg over 2-4 weeks unless side effects necessitate slower titration.
Critical Monitoring Considerations
The abrupt discontinuation without taper is concerning for two reasons:
Withdrawal symptoms: While one pediatric study found that gradual tapering of nortriptyline prevented withdrawal symptoms in most patients 2, your patient stopped abruptly. The 3-week gap suggests any acute withdrawal has likely resolved, but you should still inquire about symptoms experienced during discontinuation.
Symptom recurrence risk: Guidelines emphasize that the greatest relapse risk occurs in the first 8-12 weeks after stopping antidepressants 3. At 3 weeks post-discontinuation, this patient is in the high-risk window for symptom return. Close monitoring is essential.
Follow-Up Schedule
Weekly contact (in-person or telephone) for the first month is appropriate given:
- The dose escalation period
- The high-risk window for symptom recurrence 3
- Need to assess tolerability at each dose increase
After reaching the target dose, transition to monthly monitoring for at least 6 months to ensure sustained response 3.
Common Pitfalls to Avoid
- Do not restart at 100 mg: This risks intolerable side effects and poor adherence
- Do not assume the patient will tolerate the same dose: Three weeks off medication is sufficient time for receptor changes
- Do not neglect to explore why the medication was stopped: Understanding the reason for discontinuation (side effects, perceived inefficacy, cost, stigma) is critical to preventing future non-adherence 4
- Do not forget baseline assessment: Before restarting, document current symptom severity to distinguish treatment response from natural fluctuation
Special Considerations
If the patient is elderly, start even lower (30 mg daily) and titrate more slowly, as the FDA label specifically recommends 30-50 mg/day in divided doses for elderly patients 1. Elderly patients also have higher plasma concentrations of the active metabolite 10-hydroxynortriptyline, which has been associated with cardiotoxicity even when nortriptyline levels are therapeutic 1.